Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COYANASDAQ:MGTANASDAQ:NXTCNASDAQ:RAIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOYACoya Therapeutics$5.56-0.7%$5.92$4.65▼$10.24$92.91M0.4972,297 shs5,521 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsNXTCNextCure$0.50+6.5%$0.43$0.22▼$1.82$13.86M1.04105,274 shs72,744 shsRAINRain Oncology$4.45+1.6%$1.21$0.82▼$11.32$24.65M-0.1132,376 shs11,637 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOYACoya Therapeutics-1.58%-1.23%-9.24%-16.79%-27.93%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%NXTCNextCure-5.18%-7.88%+0.37%-39.34%-69.11%RAINRain Oncology+4.41%-36.20%+48.47%+89.61%+261.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOYACoya Therapeutics2.0161 of 5 stars3.53.00.00.02.60.80.0MGTAMagenta TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.2941 of 5 stars3.53.00.04.32.51.71.3RAINRain OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOYACoya Therapeutics 3.00Buy$17.00205.81% UpsideMGTAMagenta Therapeutics 0.00N/AN/AN/ANXTCNextCure 3.00Buy$3.50604.23% UpsideRAINRain Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NXTC, RAIN, COYA, and MGTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/27/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/20/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/18/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/17/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/10/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOYACoya Therapeutics$3.69M25.23N/AN/A$2.47 per share2.25MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ARAINRain OncologyN/AN/A$0.60 per share7.41($0.69) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOYACoya Therapeutics-$7.99M-$1.07N/AN/AN/AN/A-31.63%-27.76%8/11/2025 (Estimated)MGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/ANXTCNextCure-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%8/7/2025 (Estimated)RAINRain Oncology$3.10MN/A0.00∞N/AN/AN/A-9.51%N/ALatest NXTC, RAIN, COYA, and MGTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RAINRain OncologyN/A-$0.20N/A-$0.20N/AN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/6/2025Q4 2024NXTCNextCure-$0.34-$0.41-$0.07-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOYACoya TherapeuticsN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ARAINRain OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOYACoya TherapeuticsN/A15.3115.31MGTAMagenta TherapeuticsN/A19.4919.49NXTCNextCureN/A9.079.07RAINRain OncologyN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOYACoya Therapeutics39.75%MGTAMagenta Therapeutics47.53%NXTCNextCure42.65%RAINRain Oncology25.79%Insider OwnershipCompanyInsider OwnershipCOYACoya Therapeutics12.00%MGTAMagenta Therapeutics15.18%NXTCNextCure17.90%RAINRain Oncology17.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableNXTCNextCure9028.05 million24.28 millionOptionableRAINRain Oncology635.54 million4.57 millionNo DataNXTC, RAIN, COYA, and MGTA HeadlinesRecent News About These Companies'AI Can Detect Cancer, But Bengaluru Still Can’t Handle Rain?' Investor's Viral Rant Sparks DebateMay 21, 2025 | msn.comThousands brave rainy weather for Race For Hope to fund brain cancer researchMay 9, 2025 | msn.comPart of Horn Island is up for sale, listed for $25MMay 9, 2025 | wlox.com10-year-old cancer survivor rings bell, throws first pitch at Space Cowboys gameMay 3, 2025 | msn.comLead singer for popular U.K. rock band dies at 66May 1, 2025 | msn.comMike Peters Dies: The Alarm’s Frontman Was 66May 1, 2025 | msn.comThey Can’t Rain on Her ParadeApril 14, 2025 | capemaycountyherald.comToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comBrain cancer: Recognising tumour symptoms, risk factors and seeking treatmentNovember 24, 2024 | msn.comStars shine despite rain on Illinois’ Night of ChampionsNovember 15, 2024 | harnessracingupdate.comUI researcher wins $10 million dollars to combat ovarian cancerNovember 14, 2024 | kwwl.com'Smart freeway' to cut commute for thousands of Perth motoristsNovember 14, 2024 | 9news.com.auIcy spots possible Wednesday morning as temperatures fall below freezingNovember 13, 2024 | atlantic.ctvnews.caNewfoundland man electrocuted by downed power line, two women injuredNovember 11, 2024 | msn.comKing Charles III and Kate attend remembrance events as both slowly return to dutyNovember 11, 2024 | msn.comPrince William describes family's ‘brutal’ year as wife and father faced cancer treatmentNovember 8, 2024 | msn.comThe Eras Tour kept me going during my breast cancer treatmentNovember 8, 2024 | theglobeandmail.comSheila Jackson Lee’s daughter to finish her mother’s term before former Houston mayor takes 18th Congressional DistrictNovember 7, 2024 | click2houston.comRecap: Wisconsin voters go to the polls for 2024 electionNovember 6, 2024 | celticswire.usatoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, RAIN, COYA, and MGTA Company DescriptionsCoya Therapeutics NASDAQ:COYA$5.56 -0.04 (-0.73%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.NextCure NASDAQ:NXTC$0.50 +0.03 (+6.54%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Rain Oncology NASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
